Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 101.30

-2.5%

Nov 19 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (689)	7/30/1998 10:23:00 AM
From: rkrw	Read Replies (1) of 3202

Bluegreen, This helps people make money in risky biotechs in many ways. The differences in management and capability between XOMA and INCY is about as broad as you get. Whereas INCY has had a keen eye on shareholder value and dilution for its entire existence, XOMA has dropped the ball countless times and has treated shareholders as nothing more than a financing tool. This difference in philosophy has shown itself in the putrid returns of XOMA and returns among the best of all of biotech for INCY. To take it a step further, XOMA has screwed shareholders again and again, whereas INCY has conceived and executed a brilliant business plan that is now being emulated by others. I would not call INCY a risky biotech investment by any standard. Obviously you believe that the tide has turned and XOMA is headed in the right direction. That has yet to be shown.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next